Temprian Oncology

Temprian Oncology is a biotechnology company focused on developing novel immunotherapies for the treatment of cancer by modulating the Heat Shock Protein 70 (HSP70) pathway. The company utilizes a proprietary DNA vaccine platform designed to trigger a robust and specific immune response against malignant cells that overexpress HSP70. This approach aims to provide a targeted therapeutic option for patients with solid tumors, with a primary research focus on melanoma. Closely related to Temprian Therapeutics, which applies similar technology to autoimmune conditions, Temprian Oncology leverages decades of academic research into proteostasis and immune regulation. The company's mission is to advance next-generation cancer vaccines that are both highly effective and minimally toxic compared to conventional treatments.